Kalamazoo, Michigan, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced today that it has priced the following
notes: (i) €550 million aggregate principal amount of the Company’s 1.125% Notes due 2023 (the “2023 Notes”), (ii) €750 million
aggregate principal amount of the Company’s 2.125% Notes due 2027 (the “2027 Notes”), (iii) €650 million aggregate principal amount
of the Company’s 2.625% Notes due 2030 (the “2030 Notes”) and (iv) €300 million aggregate principal amount of the Company’s
Floating Rate Notes due 2020 (the “Floating Rate Notes” and together with the 2023 Notes, 2027 Notes and 2030 Notes, the
“Notes”). Unless previously redeemed pursuant to their terms, if applicable, the 2023 Notes will mature on November 30, 2023,
the 2027 Notes will mature on November 30, 2027, the 2030 Notes will mature on November 30, 2030 and the Floating Rate Notes will
mature on November 30, 2020. The Notes are expected to settle on November 30, 2018, subject to the satisfaction of customary
closing conditions.
The Company intends to use the net proceeds from the offering for general corporate purposes, including the repayment of all of
the $500 million principal amount of outstanding 1.800% Notes due January 15, 2019 at maturity and the repayment of all of the $750
million principal amount of outstanding 2.000% Notes due March 8, 2019 at maturity, as well as the repayment of any commercial
paper then outstanding.
Barclays Bank PLC, BNP Paribas, Goldman Sachs & Co. LLC and J.P. Morgan Securities plc are acting as active joint book-running
managers for the offering. This offering was made pursuant to a prospectus supplement, filed today, to the Company’s prospectus,
dated February 12, 2016, filed as part of the Company’s effective shelf registration statement. Copies of the preliminary
prospectus supplement and accompanying prospectus relating to the notes may be obtained by contacting: (i) Barclays Bank PLC, 5 The
North Colonnade, Canary Wharf, London E14 4BB, United Kingdom, or by calling 1-888-603-5847 or emailing
barclaysprospectus@broadridge.com, (ii) BNP Paribas, 10 Harewood Avenue, London NW1 6AA, United Kingdom, or by calling
1-800-854-5674, (iii) Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, or by calling (866)
471-2526, by faxing (212) 902-9316 or emailing prospectus-ny@ny.email.gs.com or (iv) J.P. Morgan Securities plc, 25 Bank Street,
Canary Wharf, London E14 5JP, United Kingdom, or by calling collect on +44-207-134-2468.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be
any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any such state or other jurisdiction.
Forward-looking statements
This press release contains information that includes or is based on forward-looking statements within the meaning of the
federal securities law that are subject to various risks and uncertainties that could cause our actual results to differ materially
from those expressed or implied in such statements. Such factors include, but are not limited to: weakening of economic conditions
that could adversely affect the level of demand for our products; pricing pressures, including cost-containment measures that could
adversely affect the price of or demand for our products; changes in foreign exchange markets; legislative and regulatory actions;
unanticipated issues arising in connection with clinical studies and otherwise that affect U.S. Food and Drug Administration
approval of new products; potential supply disruptions; changes in reimbursement levels from third-party payors; a significant
increase in product liability claims; the ultimate total cost with respect to the Rejuvenate and ABG II recall matter; the impact
of investigative and legal proceedings and compliance risks; resolution of tax audits; the impact of the federal legislation to
reform the United States healthcare system; changes in financial markets; changes in the competitive environment; our ability to
integrate acquisitions; and our ability to realize anticipated cost savings. Additional information concerning these and other
factors is contained in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q.
Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make
healthcare better. The Company offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology
and Spine that help improve patient and hospital outcomes.
Contacts
For investor inquiries please contact:
Katherine A. Owen, Stryker, 269-385-2600 or katherine.owen@stryker.com
For media inquiries please contact:
Yin Becker, Stryker, 269-385-2600 or yin.becker@stryker.com
